Aerpio Pharmaceuticals (NASDAQ:ARPO) Lifted to Buy at ValuEngine

ValuEngine upgraded shares of Aerpio Pharmaceuticals (NASDAQ:ARPO) from a hold rating to a buy rating in a report issued on Wednesday, ValuEngine reports.

Separately, BTIG Research assumed coverage on shares of Aerpio Pharmaceuticals in a research report on Wednesday, December 9th. They set a buy rating and a $4.00 price target for the company.

ARPO opened at $0.98 on Wednesday. Aerpio Pharmaceuticals has a 12-month low of $0.42 and a 12-month high of $2.31. The stock has a market cap of $46.17 million, a price-to-earnings ratio of -9.80 and a beta of 2.14. The stock’s 50 day simple moving average is $1.50.

Aerpio Pharmaceuticals Company Profile

Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing compounds for the treatment of ocular diseases and diabetic complications. The company's lead product candidate is razuprotafib, a small molecule activator of the Tie2 pathway, which completed the Phase IIb clinical trial for the treatment of diabetic retinopathy.

Featured Story: How does a reverse stock split work?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.